Arrowhead Pharmaceuticals, Inc. (ARWR)
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
Loses money on what it sells.
- Revenue
- $669.5M
- Net income
- -$320.0M
- Net margin
- -47.8%
Heavily indebted for what it earns.
- Total debt
- $864.1M
- Cash
- $54.8M
- Debt / equity
- 1.86
Comfortably covers what is due within a year.
- Current assets
- $1.67B
- Current liabilities
- $283.3M
- Current ratio
- 5.90
Consumes cash and must keep raising it.
- Operating cash flow
- -$59.1M
- Free cash flow
- -$75.1M
- FCF margin
- -11.2%
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 143.4M
- Share growth (1y)
- 3.1%
- Cash runway
- 11 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ARWR Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 75.25 M | 73.74 M | 264.03 M | 256.47 M | 27.77 M | 542.71 M |
| Revenue Growth (YoY) | 171.02 % | -86.41 % | 10461.32 % | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 75.25 M | 73.74 M | 264.03 M | 256.47 M | 27.77 M | 542.71 M |
| SG&A Expense | 47.12 M | 41.24 M | 45.52 M | 37.18 M | 30.44 M | 27.89 M |
| R&D Expense | 198.22 M | 173.25 M | 177.20 M | 174.69 M | 162.37 M | 133.10 M |
| Operating Expenses | 245.35 M | 215.00 M | 223.22 M | 212.37 M | 193.32 M | 161.51 M |
| Operating Income | -170.09 M | -141.26 M | 40.81 M | 44.11 M | -165.55 M | 381.20 M |
| Pretax Income | -178.91 M | -137.56 M | 28.27 M | 36.12 M | -179.09 M | 369.62 M |
| Tax Provision | 11.00 K | 7.00 K | 29.00 K | 20.00 M | -437.00 K | 1.75 M |
| Net Income | -194.28 M | -132.73 M | 30.81 M | -23.75 M | -175.24 M | 370.44 M |
| EPS (Basic) | -1.36 | -0.93 | 0.22 | -0.17 | -1.26 | 2.78 |
| EPS (Diluted) | -1.36 | -0.93 | 0.22 | -0.17 | -1.26 | 2.75 |
| Shares Outstanding | 143.38 M | 142.42 M | 140.05 M | 135.70 M | 139.04 M | 133.36 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.